Novartis responds to ongoing corruption investigations
Novartis has issued a response concerning ongoing corruption investigations by both Greek and U.S. authorities.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
ArticleNovartis sets aside $700M in kickback case
Swiss pharmaceutical drug maker Novartis announced it has set aside $700 million for a potential settlement in a long-running lawsuit over allegations that the company paid hundreds of millions of dollars in kickbacks to doctors to induce them into prescribing drugs to patients to boost their sales.
-
Article
Distilling compliance lessons from Novartis
Ethics and compliance officers in the pharmaceutical industry can learn a lot from the troubles of Novartis, which faced a firestorm of criticism from shareholders at its last annual meeting.
-
ArticleHow to establish an anti-corruption and anti-bribery compliance program
The U.K. unveiled a new Anti-Corruption Strategy in December 2025, just as the EU unveiled its first Anti-Corruption Directive. Both jurisdictions have signalled that they are keen to push back on rising risks of corruption. But many organizations have no formal anti-corruption measures. Where should compliance start?